Regulation of NF-κB signaling by the A20 deubiquitinase

Cellular and Molecular Immunology

Volumn 9, Issue 2, 2012, Pages 123-130

  Shembade, Noula ^a   Harhaj, Edward W ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

A20; inflammation; NF B; ubiquitin

Indexed keywords

A20 PROTEIN; BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; PROTEIN AIP 4; REGULATOR PROTEIN; RING FINGER PROTEIN 11; TAX1 BINDING PROTEIN 1; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; UBIQUITINATION;

ANIMALS; AUTOIMMUNE DISEASES; DNA-BINDING PROTEINS; HUMANS; I-KAPPA B KINASE; IMMUNITY, INNATE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOMA, B-CELL; MICE; MICE, KNOCKOUT; NF-KAPPA B; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

MUS;

EID: 84858120447     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2011.59     Document Type: Review

References (108)

1. Hayden MS, Ghosh S. Shared principles in NF-kB signaling. Cell 2008; 132: 344-362.
2. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev 2004; 18: 2195-2224.
3. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006; 2006: re13.
4. Sun SC, Ganchi PA, Ballard DW, Greene WC. NF-kB controls expression of inhibitor IkBa: evidence for an inducible autoregulatory pathway. Science 1993; 259: 1912-1915. (Pubitemid 23124465)
5. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-479. (Pubitemid 28411135)
6. Bernassola F, Karin M, Ciechanover A, Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 2008; 14: 10-21. (Pubitemid 351885498)
7. Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular signals. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 2008; 9: 536-542. (Pubitemid 351772916)
8. Tokunaga F, Sakata S, Saeki Y, Satomi Y, Kirisako T, Kamei K et al. Involvement of linear polyubiquitylation of NEMO in NF-kB activation. Nat Cell Biol 2009; 11: 123-132.
9. Iwai K, Tokunaga F. Linear polyubiquitination: a new regulator of NF-kB activation. EMBO Rep 2009; 10: 706-713.
10. Ikeda F, Deribe YL, Skanland SS, Stieglitz B, Grabbe C, Franz-Wachtel M et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-kB activity and apoptosis. Nature 2011; 471: 637-641.
11. Deng L, Wang C, Spencer E, Yang L, Braun A, You J et al. Activation of the IkB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103: 351-361.
12. Dynek JN, Goncharov T, Dueber EC, Fedorova AV, Izrael-Tomasevic A, Phu L et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J 2010; 29: 4198-4209.
13. Deng L, Wang C, Spencer E, Yang L, Braun A, You J et al. Activation of the IkB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103: 351-361.
14. Dynek JN, Goncharov T, Dueber EC, Fedorova AV, Izrael-Tomasevic A, Phu L et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J 2010; 29: 4198-4209.
15. Matsumoto ML, Wickliffe KE, Dong KC, Yu C, Bosanac I, Bustos D et al. K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody. Mol Cell 2010; 39: 477-484.
16. Chastagner P, Israel A, Brou C. AIP4/Itch regulates Notch receptor degradation in the absence of ligand. PLoS ONE 2008; 3: e2735.
17. Wertz IE, Dixit VM. Ubiquitin-mediated regulation of TNFR1 signaling. Cytokine Growth Factor Rev 2008; 19: 313-324.
18. O'Donnell MA, Legarda-Addison D, Skountzos P, Yeh WC, Ting AT. Ubiquitination of RIP1 regulates an NF-kB-independent cell-death switch in TNF signaling. Curr Biol 2007; 17: 418-424.
19. Gerlach B, Cordier SM, Schmukle AC, Emmerich CH, Rieser E, Haas TL et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 2011; 471: 591-596.
20. Kanayama A, Seth RB, Sun L, Ea CK, Hong M, Shaito A et al. TAB2 and TAB3 actvate the NF-kB pathway through binding to polyubiquitin chains. Mol Cell 2004; 15: 535-548. (Pubitemid 39141781)
21. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFa requires sitespecific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 2006; 22: 245-257.
22. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitindependent kinase of MKK and IKK. Nature 2001; 412: 346-351. (Pubitemid 32694385)
23. Akira S. Toll-like receptor signaling. J Biol Chem 2003; 278: 38105-38108. (Pubitemid 37221695)
24. Jiang Z, Ninomiya-Tsuji J, Qian Y, Matsumoto K, Li X. Interleukin-1 (IL-1) receptorassociated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol. Mol Cell Biol 2002; 22: 7158-7167.
25. Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitinspecific deubiquitinating enzymes. Annu Rev Biochem 2009; 78: 363-397.
26. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005; 123: 773-786. (Pubitemid 41721026)
27. Ambroggio XI, Rees DC, Deshaies RJ. JAMM: a metalloprotease-like zinc site in the proteasome and signalosome. PLoS Biol 2004; 2: E2.
28. Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009; 10: 550-563.
29. Harhaj EW, Dixit VM. Deubiquitinases in the regulation of NF-kB signaling. Cell Res 2011; 21: 22-39.
30. Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-kB activation and diverse biological processes. Cell Death Differ 2010; 17: 25-34.
31. OpipariAW Jr, Boguski MS, Dixit VM. The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem 1990; 265: 14705-14708.
32. Krikos A, Laherty CD, Dixit VM. Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kB elements. J Biol Chem 1992; 267: 17971-17976.
33. Laherty CD, Perkins ND, Dixit VM. Human T cell leukemia virus type I Tax and phorbol 12-myristate 13-acetate induce expression of the A20 zinc finger protein by distinct mechanisms involving nuclear factor kB. J Biol Chem 1993; 268: 5032-5039. (Pubitemid 23081627)
34. Opipari AW Jr, Hu HM, Yabkowitz R, Dixit VM. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem 1992; 267: 12424-12427.
35. Jaattela M, Mouritzen H, Elling F, Bastholm L. A20 zinc finger protein inhibits TNF and IL-1 signaling. J Immunol 1996; 156: 1166-1173. (Pubitemid 26048113)
36. Song HY, Rothe M, Goeddel DV. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kB activation. Proc Natl Acad Sci USA 1996; 93: 6721-6725. (Pubitemid 26230376)
37. Heyninck K, de Valck D, Vanden Berghe W, van Criekinge W, Contreras R, FiersWet al. The zinc finger protein A20 inhibits TNF-induced NF-kB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kB-inhibiting protein ABIN. J Cell Biol 1999; 145: 1471-1482. (Pubitemid 29310004)
38. Heyninck K, Beyaert R. The cytokine-inducible zinc finger protein A20 inhibits IL-1- induced NF-kB activation at the level of TRAF6. FEBS Lett 1999; 442: 147-150. (Pubitemid 29070823)
39. Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP et al. Failure to regulate TNF-induced NF-kB and cell death responses in A20-deficient mice. Science 2000; 289: 2350-2354.
40. Evans PC Ovaa H, Hamon M, Kilshaw PJ, Hamm S, Bauer S et al. Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J 2004; 378: 727-734. (Pubitemid 38406847)
41. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind LSeshagiri S et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kB signalling. Nature 2004; 430: 694-699. (Pubitemid 39061687)
42. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C et al. The ubiquitinmodifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004; 5: 1052-1060. (Pubitemid 41057725)
43. Shembade N, Ma A, Harhaj EW. Inhibition of NF-kB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010; 327: 1135-1139.
44. Bosanac I, Wertz IE, Pan B, Yu C, Kusam S, Lam Cet al. Ubiquitin binding to A20 ZnF4 is required for modulation of NF-kB signaling. Mol Cell 2010; 40: 548-557.
45. Li L, Soetandyo N, Wang Q, Ye Y. The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation. Biochim Biophys Acta 2009; 1793: 346-353.
46. Klinkenberg M, van Huffel S, Heyninck K, Beyaert R. Functional redundancy of the zinc fingers of A20 for inhibition of NF-kB activation and protein-protein interactions. FEBS Lett 2001; 498: 93-97. (Pubitemid 32522898)
47. Klinkenberg M, van Huffel S, Heyninck K, Beyaert R. Functional redundancy of the zinc fingers of A20 for inhibition of NF-kB activation and protein-protein interactions. FEBS Lett 2001; 498: 93-97.
48. Skaug B, Chen J, Du F, He J, Ma A, Chen ZJ. Direct, Noncatalytic Mechanism of IKK Inhibition by A20. Mol Cell 2011; 44: 559-571.
49. Tewari M, Wolf FW, Seldin MF, O'Shea KS, Dixit VM, Turka LA. Lymphoid expression and regulation of A20, an inhibitor of programmed cell death. J Immunol 1995; 154: 1699-1706.
50. Turer EE, Tavares R, Hitotsumatsu O, Advincula R, Lee BL, Shifrin N et al. Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20. J Exp Med 2008; 205: 451-464. (Pubitemid 351281609)
51. Tavares RM, Turer EE, Liu C-L, Advincula R, Scapini P, Rhee L et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 2010; 33: 181-191.
52. Tavares RM, Turer EE, Liu C-L, Advincula R, Scapini P, Rhee L et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 2010; 33: 181-191.
53. Chu Y, Vahl JC, Kumar D, Heger K, Bertossi A, Wo jtowicz E et al. B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood 2011; 117: 2227-2236.
54. Hovelmeyer N, Reissig S, Xuan NT, Adams-Quack P, Lukas D, Nikolaev A et al. A20 deficiency in B cells enhances B-cell proliferation and results in the development of autoantibodies. Eur J Immunol 2011; 41: 595-601.
55. Hammer GE, Turer EE, Taylor KE, Fang CJ, Advincula R, Oshima S et al. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol 2011; 12: 1184-1193.
56. Kool M, van Loo G, Waelput W, de Prijck S, Muskens F, Sze M et al. The ubiquitinediting protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity 2011; 35: 82-96.
57. Song XT, Evel-Kabler K, Rollins L, Aldrich M, Huang XF, Chen SY. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med 2008; 14: 258-265. (Pubitemid 351347913)
58. Arsenescu R, Bruno ME, Rogier EW, Stefka AT, McMahan AE, Wright TB et al. Signature biomarkers in Crohn's disease: toward a molecular classification. Mucosal Immunol 2008; 1: 399-411.
59. Vereecke L, Sze M, Mc Guire C, Rogiers B, Chu Y, Schmidt-Supprian M et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med 2010; 207: 1513-1523.
60. Kolodziej LE, Jacques P, Maelfait J, Verheugen E, Kool M, Sze M et al. TNFAIP3 maintains intestinal barrier function and supports epithelial cell tight junctions. PLoS ONE 2011; 6: e26352.
61. Matmati M, Jacques P, Maelfait J, Verheugen E, Kool M, Sze M et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 2011; 43: 908-912.
62. Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, BurttNPet al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 2008; 40: 1216-1223.
63. Lippens S, Lefebvre S, Gilbert B, Sze M, Devos M, Verhelst K et al. Keratinocytespecific ablation of the NF-kB regulatory protein A20 (TNFAIP3) reveals a role in the control of epidermal homeostasis. Cell Death Differ. 2011; 18: 1845-1853.
64. Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, NúñezGet al. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kB activation. EMBO J 2008; 27: 373-383. (Pubitemid 351161652)
65. Hitotsumatsu O, Ahmad RC, Tavares R, Wang M, Philpott D, Turer EE et al. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 2008; 28: 381-390. (Pubitemid 351343859)
66. Blonska M, Lin X. NF-kB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res 2011; 21: 55-70.
67. Duwel M, Welteke V, Oeckinghaus A, Baens M, Kloo B, Ferch U et al. A20 negatively regulates T cell receptor signaling to NF-kB by cleaving Malt1 ubiquitin chains. J Immunol 2009; 182: 7718-7728.
68. Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kB inhibitor A20. Nat Immunol 2008; 9: 263-271. (Pubitemid 351267323)
69. Komander D, Reyes-Turcu F, Licchesi JD, Odenwaelder P, Wilkinson KD, Barford D. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep 2009; 10: 466-473.
70. Gachon F, Peleraux A, Thebault S, Dick J, Lemasson I, Devaux C et al. CREB-2, a cellular CRE-dependent transcription repressor, functions in association with Tax as an activator of the human T-cell leukemia virus type 1 promoter. J Virol 1998; 72: 8332-8337. (Pubitemid 28421833)
71. de Valck D, Jin DY, Heyninck K, van de Craen M, Contreras R, Fiers W et al. The zinc finger protein A20 interacts with a novel anti-apoptotic protein which is cleaved by specific caspases. Oncogene 1999; 18: 4182-4190. (Pubitemid 29377849)
72. Ling L, Goeddel DV. T6BP, a TRAF6-interacting protein involved in IL-1 signaling. Proc Natl Acad Sci USA 2000; 97: 9567-9572. (Pubitemid 30650816)
73. Iha H, Peloponese JM, Verstrepen L, Zapart G, Ikeda F, Smith CD et al. Inflammatory cardiac valvulitis in TAX1BP1-deficient mice through selective NF-kB activation.EMBO J 2008; 27: 629-641. (Pubitemid 351273127)
74. Shembade N, Harhaj NS, Liebl DJ, Harhaj EW. Essential role for TAX1BP1 in the termination of TNF-a-, IL-1- and LPS-mediated NF-kB and JNK signaling. EMBO J2007; 26: 3910-3922.
75. Kitching R, Wong MJ, Koehler D, Burger AM, Landberg G, Gish G et al. The RING-H2 protein RNF11 is differentially expressed in breast tumours and interacts with HECTtype E3 ligases. Biochim Biophys Acta 2003; 1639: 104-112. (Pubitemid 38366214)
76. Sudol M, Chen HI, Bougeret C, Einbond A, Bork P. Characterization of a novel proteinbinding module-the WW domain. FEBS Lett 1995; 369: 67-71.
77. Shembade N, Harhaj NS, Parvatiyar K, Copeland NG, Jenkins NA, Matesic LE et al. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat Immunol 2008; 9: 254-262. (Pubitemid 351276830)
78. Matesic LE, Copeland NG, Jenkins NA. Itchy mice: the identification of a new pathway for the development of autoimmunity. Curr Top Microbiol Immunol 2008; 321: 185-200.
79. Subramaniam V, Li H, Wong M, Kitching R, Attisano L, Wrana J et al. The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase. Br J Cancer 2003; 89: 1538-1544. (Pubitemid 37386612)
80. Azmi P, Seth A. RNF11 is a multifunctional modulator of growth factor receptor signalling and transcriptional regulation. Eur J Cancer 2005; 41: 2549-2560. (Pubitemid 41541975)
81. Santonico E, Belleudi F, Panni S, Torrisi MR, Cesareni G, Castagnoli L. Multiple modification and protein interaction signals drive the Ring finger protein 11 (RNF11) E3 ligase to the endosomal compartment. Oncogene 2010; 29: 5604-5618.
82. Colland F, Jacq X, Trouplin V, Mougin C, Groizeleau C, Hamburger A et al. Functional proteomics mapping of a human signaling pathway. Genome Res 2004; 14: 1324-1332. (Pubitemid 39029229)
83. Shembade N, Parvatiyar K, Harhaj NS, Harhaj EW. The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kB signalling. EMBO J 2009; 28: 513-522.
84. Heyninck K, Kreike MM, Beyaert R. Structure-function analysis of the A20-binding inhibitor of NF-kB activation, ABIN-1. FEBS Lett 2003; 536: 135-140. (Pubitemid 36206420)
85. Mauro C, Pacifico F, Lavorgna A, Mellone S, Iannetti A. ABIN-1 binds to NEMO/IKKγ and co-operates with A20 in inhibiting NF-kB. J Biol Chem 2006; 281: 18482-18488. (Pubitemid 44035507)
86. Oshima S, Turer EE, Callahan JA, Chai S, Advincula R, Barrera J et al. ABIN-1 is a ubiquitin sensor that restricts cell death and sustains embryonic development. Nature 2009; 457: 906-909.
87. Zhou J, Wu R, High AA, Slaughter CA, Finkelstein D, Rehg JE et al. A20-binding inhibitor of NF-κB (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancerbinding protein beta activation and protects from inflammatory disease. Proc Natl Acad Sci USA 2011; 108: E998-E1006.
88. Wagner S, Carpentier I, Rogov V, Kreike M, Ikeda F, Löhr F et al. Ubiquitin binding mediates the NF-kB inhibitory potential of ABIN proteins. Oncogene 2008; 27: 3739-3745. (Pubitemid 351912974)
89. Nanda SK, Venigalla RK, Ordureau A, Patterson-Kane JC, Powell DW, Toth R et al. Polyubiquitin binding to ABIN1 is required to prevent autoimmunity. J Exp Med 2011; 208: 1215-1228.
90. Vincenz C, Dixit VM. 14-3-3 proteins associate with A20 in an isoform-specific manner and function both as chaperone and adapter molecules. J Biol Chem 1996; 271: 20029-20034. (Pubitemid 26281752)
91. de Valck D, Heyninck K, van Criekinge W, Vandenabeele P, Fiers W, Beyaert R. A20 inhibits NF-kB activation independently of binding to 14-3-3 proteins. Biochem Biophys Res Commun 1997; 238: 590-594. (Pubitemid 27464433)
92. Bohgaki M, Tsukiyama T, Nakajima A, Maruyama S, Watanabe M, Koike T et al. Involvement of Ymer in suppression of NF-kB activation by regulated interaction with lysine-63-linked polyubiquitin chain. Biochim Biophys Acta 2008; 1783: 826-837. (Pubitemid 351508338)
93. Shembade N, Pujari R, Harhaj NS, Abbott DW, Harhaj EW. The kinase IKKa inhibits activation of the transcription factor NF-κB by phosphorylating the regulatory molecule TAX1BP1. Nat Immunol 2011; 12: 834-843.
94. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature 2005; 434: 1138-1143. (Pubitemid 40663493)
95. Li Q, Lu Q, Bottero V, Estepa G, Morrison L, Mercurio F et al. Enhanced NF-κB activation and cellular function in macrophages lacking IκB kinase 1 (IKK1). Proc Natl Acad Sci USA 2005; 102: 12425-12430. (Pubitemid 41266375)
96. Hutti JE, Abbott DW, Zhou AY, Sprott KM, Asara JM, Hahn WC. IKKb Phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kB pathway. Mol Cell Biol 2007; 27: 7451-7461. (Pubitemid 350033652)
97. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, ShenQ et al. Mutations of multiple genes cause deregulation of NF-kB in diffuse large B-cell lymphoma. Nature 2009; 459: 717-721.
98. Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009; 459: 712-716.
99. Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009; 114: 246-275.
100. Chanudet E, Huang Y, Ichimura K, Dong G, Hamoudi RA, Radford J et al. A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia 2010; 24: 483-487.
101. Schmitz R, Hansmann M-L, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009; 206: 981-989.
102. Braun FC, Grabarczyk P, Möbs M, Braun FK, Eberle J, BeyerMet al. Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sezary syndrome. Leukemia 2011; 25: 1494-1501.
103. Ferch U, Kloo B, Gewies A, Pfänder V, Düwel M, Peschel C et al. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2009; 206: 2313-2320.
104. Vendrell JA, Ghayad S, Ben-Larbi S, Dumontet C, Mechti N, Cohen PA. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene 2007; 26: 4656-4667. (Pubitemid 47067412)
105. Guo Q, Dong H, Liu X, Wang C, Liu N, Zhang J et al. A20 is overexpressed in glioma cells and may serve as a potential therapeutic target. Expert Opin Ther Targets 2009; 13: 733-741.
106. Hjelmeland AB, Wu Q, Wickman S, Eyler C, Heddleston J, Shi Q et al. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol 2010; 8: e1000319.
107. Sun SC. Deubiquitylation and regulation of the immune response. Nat Rev Immunol 2008; 8: 501-511.
108. Ahmed N, Zeng M, Sinha I, Polin L, Wei WZ, Rathinam C et al. The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat Immunol 2011; 12: 1176-1183